三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LABU 三倍做多标普生物-Direxion

休市中 03-20 16:00:00 EDT

142.74

-7.27

-4.85%

盘后145.56

+2.82+1.98%

19:59 EDT

最高154.44	最低139.62	成交量73.28万
今开148.70	昨收150.01	日振幅9.88%
总市值4.60亿	流通市值4.60亿	总股本322.45万
成交额1.08亿	换手率22.73%	流通股本322.45万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多标普生物-Direxion","latestPrice":142.74,"timestamp":1774036800000,"preClose":150.01,"halted":0,"volume":732793,"hourTrading":{"tag":"盘后","latestPrice":145.56,"preClose":142.74,"latestTime":"19:59 EDT","volume":25411,"amount":3662385.6755,"timestamp":1774051171546,"change":2.82,"changeRate":0.019756,"amplitude":0.029985},"delay":0,"changeRate":-0.048463435770948485,"floatShares":3224486,"shares":3224486,"eps":0,"marketStatus":"休市中","change":-7.27,"latestTime":"03-20 16:00:00 EDT","open":148.7,"high":154.44,"low":139.6201,"amount":107840111.52209,"amplitude":0.098793,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":150.01,"sharesOutstanding":3024486,"nav":150.203,"aum":491838657.02,"dividendRate":0.009353,"bidAskSpread":0.002472,"preHourTrading":{"tag":"盘前","latestPrice":149.08,"preClose":150.01,"latestTime":"09:29 EDT","volume":2670,"amount":395890.9659,"timestamp":1774013390002,"change":-0.93,"changeRate":-0.0062,"amplitude":0.028865},"postHourTrading":{"tag":"盘后","latestPrice":145.56,"preClose":142.74,"latestTime":"19:59 EDT","volume":25411,"amount":3662385.6755,"timestamp":1774051171546,"change":2.82,"changeRate":0.019756,"amplitude":0.029985},"volumeRatio":1.126117,"impliedVol":1.0281,"impliedVolPercentile":0.8486},"requestUrl":"/m/hq/s/LABU","defaultTab":"news","newsList":[{"id":"1139305073","title":"医疗保健板块综述：市场观点","url":"https://stock-news.laohu8.com/highlight/detail?id=1139305073","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139305073?lang=zh_cn&edition=full","pubTime":"2026-03-19 16:25","pubTimestamp":1773908729,"startTime":"0","endTime":"0","summary":"最新发布的医疗保健板块市场观点。0128 GMT——马来亚银行投资银行分析师Wong Wei Sum在一份报告中指出，中东冲突导致的合成橡胶市场短期中断可能对顶级手套有利。她表示，这是因为该公司能够同时生产丁腈手套和天然橡胶手套，为价格敏感的客户提供了替代选择。她表示，近期丁腈乳胶价格的上涨和供应中断可能会引发客户的复杂反应，包括恐慌性购买、暂时延迟订单以及转向天然橡胶手套。该股下跌1.7%，报0.56令吉。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TFmain","BK6103","BK4585","BVA.SI","XLV","BK4588","LABU","BK6511","XBI","BK4581"],"gpt_icon":0},{"id":"2620341297","title":"中银医疗保健混合A基金经理变动：郑宁不再担任该基金基金经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2620341297","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620341297?lang=zh_cn&edition=full","pubTime":"2026-03-19 10:02","pubTimestamp":1773885720,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年3月19日，中银医疗保健混合(005689)发布公告，郑宁不再担任该基金基金经理，离任日期为2026年3月19日，变更后中银医疗保健混合(005689)的基金经理为李文广。截止2026年3月18日，中银医疗保健混合净值为3.3907，较上一日上涨1.47%，近一年上涨43.04%。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260319/32080642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["XLV","BK4585","XBI","BK4588","BK4581","LABU"],"gpt_icon":0},{"id":"2620299991","title":"和誉-B(02256)：FGFR2/3抑制剂ABSK061 获FDA授予孤儿药资格认定 用于治疗软骨发育不全","url":"https://stock-news.laohu8.com/highlight/detail?id=2620299991","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620299991?lang=zh_cn&edition=full","pubTime":"2026-03-19 08:16","pubTimestamp":1773879410,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，本公司的附属公司上海和誉生物医药科技有限公司宣布，其自主研发的高选择性口服小分子FGFR2/3抑制剂ABSK061已获得美国食品药品监督管理局授予的孤儿药资格认定，用于治疗软骨发育不全。这是ABSK061近期获得FDA授予罕见儿科疾病资格认定后，在其全球开发进程中的又一关键里程碑。ABSK061用于治疗软骨发育不全已获得FDA授予的RPD和ODD认定，II期临床试验正在推进中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415706.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU2476274308.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LABU","LU2488822045.USD","BK4585","LU2476274720.SGD","LU2778985437.USD","IE00BPRC5H50.USD","02256","BK4588"],"gpt_icon":0},{"id":"2620259472","title":"强生治疗银屑病的口服药物获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2620259472","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620259472?lang=zh_cn&edition=full","pubTime":"2026-03-18 21:22","pubTimestamp":1773840123,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1066051811.HKD","BK4533","IE0002270589.USD","LU1894683348.USD","BK4559","IE00B42XCP33.USD","LU2347655156.SGD","LU0098860793.USD","LU0795875169.SGD","LU2468319806.SGD","IE00B4R5TH58.HKD","LU0689626769.HKD","LU0234572021.USD","BK4007","LU1066051498.USD","LU1032955483.USD","LU1244550494.USD","LU0203347892.USD","LU2133065610.SGD","LU2471134523.USD","LU1267930813.SGD","IE000M9KFDE8.USD","LU2112291526.USD","LU2750360641.GBP","IE00BVYPNV92.GBP","JNJ","LU0203345920.USD","LU2592432038.USD","LU1074936037.SGD","IE00B1BXHZ80.USD","BK4568","IE00BSNM7G36.USD","LU1496350502.SGD","BK4592","IE00B3PB1722.GBP","LU0792757196.USD","LU1023059063.AUD","LU2129689514.USD","LU2129689605.HKD","BK4581","IE00BGHQF631.EUR","IE00B2B36J28.USD","IE00BLSP4239.USD","IE00B3T34201.USD","LU1221951129.SGD","LU0122379950.USD","LU0912757837.SGD","LU0114720955.EUR","LU2430703095.HKD","LABU"],"gpt_icon":0},{"id":"2620625693","title":"FDA指出与生奶酪相关的大肠杆菌病例","url":"https://stock-news.laohu8.com/highlight/detail?id=2620625693","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620625693?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:57","pubTimestamp":1773838620,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局将美国三个州的七例大肠杆菌感染病例与Raw Farm的生切达干酪联系起来；该公司对这些发现提出异议，并在调查继续进行期间拒绝自愿召回。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-18/doc-inhrmpqh1378589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK4588","LABU"],"gpt_icon":0},{"id":"2620518239","title":"微创脑科学(02172)：APOLLO Dream®雷帕霉素靶向洗脱支架系统荣获FDA突破性医疗器械认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2620518239","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620518239?lang=zh_cn&edition=full","pubTime":"2026-03-18 17:20","pubTimestamp":1773825636,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微创脑科学 发布公告，集团自主研发的APOLLO Dream雷帕霉素靶向洗脱支架系统近期获得美国食品药品监督管理局授予的突破性医疗器械认定，成为全球首个获得该项认定的神经介入领域球囊扩张、快速交换式药物洗脱支架。APOLLO Dream支架系统专为对现有最佳药物治疗无效的症状性颅内动脉狭窄患者而设计。与传统药物支架相比，APOLLO Dream支架系统能够更加精准地控制药物释放剂量，在保证疗效的同时显著降低进入人体的总药物负荷。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415449.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09997","BK1100","BK1574","BK4585","BK4588","LABU","BK1583","159883","09996","02172","BK1222"],"gpt_icon":0},{"id":"2620276284","title":"诺华司库奇尤单抗获得美国FDA批准用于治疗12岁以上儿童中重度化脓性汗腺炎患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276284","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620276284?lang=zh_cn&edition=full","pubTime":"2026-03-18 14:06","pubTimestamp":1773813987,"startTime":"0","endTime":"0","summary":"人民财讯3月18日电，诺华宣布，司库奇尤单抗已获得美国食品药品监督管理局（FDA）批准，用于12岁及以上儿童中重度化脓性汗腺炎（HS）患者的治疗。司库奇尤单抗作为该人群中唯一获批的IL-17A抑制剂，为HS儿童患者提供了差异化的生物制剂治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603183675829931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4578","LU0320765489.SGD","BK4588","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE0002141913.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","LABU","NVS","BK4532","IE00B4R5TH58.HKD","BK4585","LU0208291251.USD","IE00BJT1NW94.SGD","LU0070302665.USD","BK4007","LU0211331839.USD"],"gpt_icon":0},{"id":"2620228933","title":"厂家提示：全球“药王”混用有风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2620228933","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620228933?lang=zh_cn&edition=full","pubTime":"2026-03-18 12:04","pubTimestamp":1773806698,"startTime":"0","endTime":"0","summary":"礼来公司近日在其官网发布了一封公开信，提示替尔泊肽与维生素B12混用会产生大量杂质，这可能给患者带来潜在的安全风险，而具体风险以及杂质如何被吸收、代谢及清除等，目前一无所知。2025年，礼来公司的替尔泊肽凭借超365亿美元的全年收入，反超诺和诺德的司美格鲁肽（361亿美元），成为全球最畅销药物，登上“药王”宝座。百亿美元的生意之下，乱象丛生。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603183675744475.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603183675744475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","LABU","BK4588"],"gpt_icon":0},{"id":"2620887102","title":"美银：AI冲击下更看好医疗保健、半导体、资本货物和保险业能长期增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2620887102","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620887102?lang=zh_cn&edition=full","pubTime":"2026-03-18 10:05","pubTimestamp":1773799514,"startTime":"0","endTime":"0","summary":"人工智能(AI)驱动的颠覆性变革为全球资本市场带来了巨大冲击。美银认为，医疗保健、半导体、资本货物和保险业更有可能在这一交汇点实现长期增长。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260318/20260318101344_55377.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260318/20260318101344_55377.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["SOXX","XLV","LABU","BK4585","XBI","BK4581","BK4588","BK4535"],"gpt_icon":0},{"id":"2620203794","title":"美国FDA拒绝批准Aldeyra眼部疾病药物，股价暴跌65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203794","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620203794?lang=zh_cn&edition=full","pubTime":"2026-03-17 21:13","pubTimestamp":1773753213,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics 公司周二表示，美国食品药品监督管理局拒绝批准其用于治疗一种眼部疾病的药物，导致该公司盘前交易股价大跌65%。Aldeyra 公司表示，监管机构并未对药物的安全性或生产工艺提出质疑。　　这是 Aldeyra 公司连续第三次遭遇挫折。自 2023 年以来，该公司围绕 reproxalap 药物已多次面临监管层面的问题。　　该公司称，目前暂无计划开展额外临床试验，而是将申请与 FDA 举行 A 型会议，商讨获得批准所需满足的条件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-17/doc-inhrieim8048729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4585","LABU","BK4588"],"gpt_icon":0},{"id":"2620924423","title":"沛嘉医疗-B(09996)：DCwire® 微导丝获FDA 510(k)许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2620924423","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620924423?lang=zh_cn&edition=full","pubTime":"2026-03-17 18:15","pubTimestamp":1773742529,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沛嘉医疗-B(09996)发布公告，由本公司附属公司加奇生物有限公司独立设计及开发的DCwire®微导丝近期已获得美国食品药品监督管理局的510(k)许可。这是本集团首个获得FDA许可的产品，也是本集团全球化战略的重要里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","BK1583","BK1574","LABU","159891","BK4585","09996","BK4588"],"gpt_icon":0},{"id":"2620442542","title":"3月17日信立泰涨5.84%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620442542","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620442542?lang=zh_cn&edition=full","pubTime":"2026-03-17 16:25","pubTimestamp":1773735915,"startTime":"0","endTime":"0","summary":"证券之星消息，3月17日信立泰涨5.84%创60日新高，收盘报58.58元，换手率1.53%，成交量17.04万手，成交额9.8亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共51家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为138.43亿元，最新净值1.7241，较上一交易日上涨0.67%，近一年上涨7.71%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/17/20260317439899.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/17/20260317439899.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260317/32074670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4588","BK0188","BK0196","002294","BK0187","159760","BK0183","BK0028","BK4585","XBI","XLV","BK0239","LABU","BK4581"],"gpt_icon":0},{"id":"2620137734","title":"雾麻科技(ISPR.US)强调FDA最新调味电子烟监管指引的经济影响 有望释放500亿美元市场 并显著提升潜在资产价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2620137734","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620137734?lang=zh_cn&edition=full","pubTime":"2026-03-17 08:27","pubTimestamp":1773707264,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，雾麻科技今日强调，U.S. Food and Drug Administration最新发布的调味电子尼古丁传递系统PMTA申请证据要求的指导草案，为公司股东创造了巨大的经济价值以及数十亿美元级别的市场机会。FDA的这一监管指引通过为调味电子烟提供合法合规的上市路径，实际上释放了一个约 500 亿美元的潜在可服务市场。IKE 的 SaaS经常性收入模式预计每位客户每年可产生 500 万至 2,000 万美元 的收入。Ispire 目前持有 IKE 合资公司 40% 的股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414656.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","ISPR","06969","BK4075","BK1580","BK1242","LABU","BK4588","BK4585"],"gpt_icon":1},{"id":"2619433979","title":"政府工作报告首次“点题”！万亿商业健康保险，走向哪里？","url":"https://stock-news.laohu8.com/highlight/detail?id=2619433979","media":"券商中国","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619433979?lang=zh_cn&edition=full","pubTime":"2026-03-16 11:22","pubTimestamp":1773631320,"startTime":"0","endTime":"0","summary":"今年政府工作报告提出要“加快发展商业健康保险，推动创新药和医疗器械高质量发展，更好满足人民群众多元化就医用药需求”，这是政府工作报告首次“点题”商业健康保险。发展潜力和主要方向在哪里？　　商业健康保险多年前就被寄予厚望。　　监管部门曾对商业健康险提出具体目标。2020年1月，原银保监会联合多部门发布《关于促进社会服务领域商业保险发展的意见》提出“力争到2025年，商业健康保险市场规模超过2万亿元”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/zqgd/2026-03-16/doc-inhrcxwx8941133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XBI","BK4588","XLV","LABU","BK4581","BK4585"],"gpt_icon":0},{"id":"2619619172","title":"葛兰素史克RSV疫苗获美国FDA批准扩大适用人群","url":"https://stock-news.laohu8.com/highlight/detail?id=2619619172","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619619172?lang=zh_cn&edition=full","pubTime":"2026-03-13 19:43","pubTimestamp":1773402180,"startTime":"0","endTime":"0","summary":"英国制药企业葛兰素史克周五宣布，美国食品药品监督管理局已扩大其呼吸道合胞病毒疫苗 Arexvy 的获批适用年龄范围，新增纳入18 至 49 岁因该病毒引发下呼吸道疾病风险升高的成年人群。该疫苗此前已在美国获批，用于60 岁及以上成年人，以及50 至 59 岁高危成年人群，预防 RSV 相关疾病。葛兰素史克表示，据估算，美国有2100 万50 岁以下成年人至少存在一项重症 RSV 感染的风险因素。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-13/doc-inhqvxri7799401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159646","GSKH","BK4007","GSK.UK","LU1829250122.USD","BK4588","BK4585","LABU","BK4532","GSK"],"gpt_icon":0},{"id":"2619115423","title":"FDA批准百时美施贵宝(BMY.US)TYK2抑制剂氘可来昔替尼治疗活动性银屑病关节炎成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2619115423","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619115423?lang=zh_cn&edition=full","pubTime":"2026-03-13 07:00","pubTimestamp":1773356416,"startTime":"0","endTime":"0","summary":"百时美施贵宝(BMY.US)宣布，美国食品药品监督管理局(FDA)已批准颂狄多®(氘可来昔替尼)用于治疗活动性银屑病关节炎(PsA)成人患者。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260313/20260313065958_28723.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260313/20260313065958_28723.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0985481810.HKD","LU0114720955.EUR","LU0868494617.USD","LU1323610961.USD","LU1868836591.USD","LU1868837136.USD","BK4532","LU1883839398.USD","LU1585245621.USD","LU1093756325.SGD","LU0456855351.SGD","LU1868837300.USD","LU2242652126.USD","LU1718418525.SGD","LU1868836914.USD","LU1261432733.SGD","LU0321505439.SGD","LU1670711123.USD","LU2125154935.USD","LU2360032135.SGD","BK4588","LU1670710588.SGD","IE00B2B36J28.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","LU1670710661.SGD","BMY","LU1032466523.USD","IE00BJT1NW94.SGD","LU1430594728.SGD","BK4007","LU1093756168.USD","BK4559","IE0002141913.USD","LU1989771016.USD","LABU","LU2125154778.USD","LU0267386448.USD","IE00BFXG1179.USD","LU0306807586.USD","BK4534","LU0306806265.USD","LU0061475181.USD","LU0882574055.USD","BK4581","LU0237698245.USD","LU0225771236.USD","LU1868836757.USD","LU0225284248.USD"],"gpt_icon":0},{"id":"2619049151","title":"阿斯利康(AZN.US)两款肿瘤药将接受FDA专家小组审判","url":"https://stock-news.laohu8.com/highlight/detail?id=2619049151","media":"智通财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619049151?lang=zh_cn&edition=full","pubTime":"2026-03-13 07:00","pubTimestamp":1773356416,"startTime":"0","endTime":"0","summary":"近日，FDA官网宣布将在2026年4月30日召开肿瘤药物咨询委员会(ODAC)会议。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260313/20260313070054_25816.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260313/20260313070054_25816.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0109394709.USD","LU0289739699.SGD","LU2456880835.USD","LU0889565916.HKD","BK4007","LU0320765992.SGD","LU2236285917.USD","BK4568","AZN","IE00B3T34201.USD","LU0058720904.USD","BK4588","LU2417539215.USD","BK4585","LU1829250122.USD","LU2462157665.USD","LABU"],"gpt_icon":0},{"id":"1153474703","title":"医疗保健板块动态：市场焦点解读","url":"https://stock-news.laohu8.com/highlight/detail?id=1153474703","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153474703?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:30","pubTimestamp":1773304243,"startTime":"0","endTime":"0","summary":"0304 GMT——野村证券分析师指出，Celltrion今年的增长动力或将来自新一代生物类似药，而非传统主力产品。Zymfentra、Yuflyma、Vegzelma及Steqeyma等新上市生物类似药有望支撑该业绩指引，而Remsima、Truxima与Herzuma等经典产品则持续提供稳定收入。分析师补充道，这些\"新生代产品组合\"占比有望突破当前50%的水平，或将推动公司开启独立于传统旗舰产品的新盈利周期。巴黎CAC 40指数下跌0.6%，主导该指数的奢侈品板块集体下挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU0321505439.SGD","LU0225284248.USD","SG9999002232.USD","LU0868494617.USD","LU1066053197.SGD","LU0234572021.USD","XLV","IE00BLSP4452.SGD","BK4533","SG9999001176.USD","SG9999011175.SGD","IE00BBT3K403.USD","IE00B19Z3581.USD","BK4550","BK4599","LU1057294990.SGD","LABU","BK4592","LU0985481810.HKD","BK4534","SG9999013999.USD","LU1883839398.USD","BK4588","LU1894683264.USD","SG9999002224.SGD","LU0225771236.USD","SG9999003800.SGD","XBI","LU0456855351.SGD","SGXZ57979304.SGD","LU0306807586.USD","IE0002270589.USD","BK4585","LU0122379950.USD","BK4581","IE00B19Z3B42.SGD","LU1894683348.USD","LU0306806265.USD","LU0170899867.USD","LU1023059063.AUD","IE00BLSP4239.USD","LU0321505868.SGD","IE000M9KFDE8.USD","LU0289739699.SGD","PFE","LU1066051498.USD","BK4568","SG9999001176.SGD","BK4007"],"gpt_icon":0},{"id":"2618944821","title":"华东医药(000963.SZ)：注射用HDM2024药品临床试验申请已获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618944821","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618944821?lang=zh_cn&edition=full","pubTime":"2026-03-11 19:42","pubTimestamp":1773229341,"startTime":"0","endTime":"0","summary":"HDM2024 由靶向EGFR/HER3 的双抗分子，可裂解的连接子及DNA拓扑异构酶1抑制剂细胞毒性分子组成。HDM2024 可同时阻断EGFR/HER3信号通路，能够有效的阻断肿瘤细胞增殖信号，同时向肿瘤细胞内释放毒素载荷，发挥肿瘤杀伤作用。临床前研究已证明HDM2024在靶点不同表达水平的多种实体瘤药效模型中显示出强大的抗肿瘤活性，具有良好的成药性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK0183","BK0196","LU1969619763.USD","BK0188","BK4588","BK0187","BK0175","BK0132","LU2328871848.SGD","BK0209","000963","LABU"],"gpt_icon":0},{"id":"2618998304","title":"和誉-B(02256)：FGFR2/3抑制剂ABSK061获FDA授予罕见儿科疾病药物资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2618998304","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618998304?lang=zh_cn&edition=full","pubTime":"2026-03-11 08:14","pubTimestamp":1773188070,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，公司的附属公司上海和誉生物医药科技有限公司宣布，其自主研发的高选择性、口服小分子FGFR2/3抑制剂ABSK061，已获得美国食品药品监督管理局授予用于治疗软骨发育不全的罕见儿科疾病药物资格认定。其口服给药方式在便捷性和治疗依从性方面具有显著优势，尤其对儿科患者而言，这使得ABSK061有望成为治疗儿童和青少年ACH患者的具有潜在价值的治疗候选药物。目前，ABSK061正在开展针对3-12岁儿童ACH患者的II期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","LU2476274308.USD","BK1161","LU2488822045.USD","02256","IE00B5MMRT66.SGD","IE00B543WZ88.USD","BK4585","LU2778985437.USD","LU2476274720.SGD","LABU","IE00BPRC5H50.USD"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.041},{"period":"1month","weight":-0.1437},{"period":"3month","weight":-0.1377},{"period":"6month","weight":0.7382},{"period":"1year","weight":0.8969},{"period":"ytd","weight":-0.1045}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.020883},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.009536},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.148177},{"month":4,"riseRate":0.4,"avgChangeRate":-0.008819},{"month":5,"riseRate":0.5,"avgChangeRate":0.005207},{"month":6,"riseRate":0.727273,"avgChangeRate":0.127955},{"month":7,"riseRate":0.636364,"avgChangeRate":0.054287},{"month":8,"riseRate":0.636364,"avgChangeRate":-0.004065},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.0652},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.047038},{"month":11,"riseRate":0.818182,"avgChangeRate":0.199161},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.032237}],"exchange":"ARCA","name":"三倍做多标普生物-Direxion","nameEN":"Direxion Daily S&P Biotech Bull 3x Shares"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三倍做多标普生物-Direxion,LABU,三倍做多标普生物-Direxion股票,三倍做多标普生物-Direxion股票老虎,三倍做多标普生物-Direxion股票老虎国际,三倍做多标普生物-Direxion行情,三倍做多标普生物-Direxion股票行情,三倍做多标普生物-Direxion股价,三倍做多标普生物-Direxion股市,三倍做多标普生物-Direxion股票价格,三倍做多标普生物-Direxion股票交易,三倍做多标普生物-Direxion股票购买,三倍做多标普生物-Direxion股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}